top of page
Our Science
We are harnessing innovations in multi-omic drug screening and cancer nanotechnology to develop a new class of synthetic lethality cancer therapeutics.
Kinome Profile Mapping
Transcriptomic RNA seq
Drug Screening
Micellar Nanocomplex
Drug Delivery Platform
Developing Transformative
Therapies for the Deadliest Cancers
Celestra Life Science is a preclinical-stage biotech startup formed by oncology leaders in academia and industry. We are committed to developing innovative medicines for the deadliest cancers.
Synthetic Lethality in RAS-activated Cancers
Our flagship drug CEL100 is a multi-kinase inhibitor that blocks key kinase effectors in all three major oncogenic pathways activated by RAS (RAF-MEK, PI3K-AKT, RalB-TBK1). CEL100 demonstrates robust single-agent activity in RAS-activated cancers across a wide diversity of tumor types and RAS alterations.
Pancreatic Ductal Adenocarcinoma
Urinary Bladder Carcinoma
Castration-Resistant Prostate Carcinoma
Our Team
Co-Founder, Chief Executive Officer
​
David Lu
MD-PhD Candidate,
Stanford School of Medicine
​
BSc Molecular Biophysics & Biochemistry,
Yale University
Co-Founder, Chief Medical Officer
​
Ray Lee, MD, PhD
Former Senior Director of Oncology,
Hoffman-La Roche
​
Former Director of Clinical Research,
Merck
​
Scientific Advisor​
​
Mark Lemmon, PhD
Co-Director,
Yale Cancer Biology Institute
​
Chair of Pharmacology,
Yale School of Medicine
​
Chief Operating Officer​
​
Evie Cai, MPH
Consulting Analyst,
Deloitte Consulting LLC
​
BA Economics, Yale University
MPH Health Policy, Yale School of Public Health
​
bottom of page